PolyPid reports US$15.5M in liquidity ahead of FDA goal date

A US$15 million partner payment has added funding ahead of an FDA review goal date as PolyPid Ltd. NASDAQPYPD reported US$15.5 million in quarter-end liquidity on Wednesday. The developer faces a Nov. 28 goal date for D-PLEX100, before a possible commercial launch in early 2027.

Its Nov. 11 results put cash, cash equivalents and short-term deposits at US$15.5 million on Sept. 30. A further US$15 million from privately held Azurity Pharmaceuticals arrived after quarter-end, so it is outside that balance.

PolyPid is a small Israeli biopharmaceutical developer focused on controlled-release medicines delivered directly at the site of treatment.

PolyPid shares NASDAQPYPD closed at US$6.31 at 4:00 p.m. EST on Nov. 10 in New York. That trading session therefore provides no measure of investors' response to the update.

Research Spending Rises As Loss Narrows

For the quarter ended Sept. 30, research and development expenses rose to US$6.5 million from US$5.3 million a year earlier. PolyPid attributed the increase to work on its drug application and preparations for commercialization.

Net loss narrowed to US$5.8 million from US$7.5 million in the September quarter. The results included US$2.5 million of other income from recognizing previously deferred revenue when its European licensing agreement ended on Sept. 30.

The post-quarter receipt takes total upfront and near-term Azurity payments received to US$30 million, according to the Nov. 11 release. More than US$290 million in further payments remains tied to regulatory, launch and sales milestones, so that potential funding is contingent.

Those milestone conditions leave holders exposed to the timing of regulatory decisions and commercial uptake while PolyPid continues spending on its application and launch preparations. The reported net loss is also distinct from operating cash consumption.

Read more: bioAffinity Technologies grows lung-test sales but flags funding needs

"We have a committed partner in Azurity preparing to bring D-PLEX100 to surgeons and patients in the U.S., subject to approval, and we now hold full rights to D-PLEX100 in Europe," chief executive Dikla Czaczkes Akselbrad said in the release.

PolyPid says the FDA is reviewing D-PLEX100 for preventing surgical site infections in patients undergoing colorectal surgery. It reports that labelling discussions are underway, with scheduled FDA interactions aligned with the goal date.

Hospital Sales And Reimbursement Remain Separate Steps

Within the hospital-drug sector, Heron Therapeutics, Inc. NASDAQHRTX reported US$10.6 million in third-quarter ZYNRELEF revenue in its Nov. 9 results. Its extended-release local anaesthetic treats postoperative pain, providing a commercial reference for local delivery around surgery.

Another local-delivery company, Pacira BioSciences, Inc. NASDAQPCRX, describes EXPAREL as a long-acting local analgesic for postsurgical pain in its Oct. 8 announcement. Those pain products provide no direct efficacy comparison with PolyPid's infection-prevention candidate.

PolyPid expects a U.S. launch in early 2027, subject to approval. A separate application for Medicare's New Technology Add-on Payment has been submitted to the Centers for Medicare & Medicaid Services, with a decision expected in August 2027.

If granted, that payment would provide additional hospital reimbursement for inpatient use. The reimbursement decision and the FDA's marketing decision are separate milestones in PolyPid's commercialization timetable.

Read more: NRx Pharmaceuticals starts ketamine sales effort ahead of January shipments

European rights have reverted to PolyPid after its licensing agreement ended, leaving it seeking a new commercial partner. The company says the European Medicines Agency validated its application after quarter-end and expects a decision in the second half of 2027.

The next regulatory milestone is the FDA's Nov. 28 goal date, when the review of whether D-PLEX100 can be marketed for preventing infections after colorectal surgery is scheduled to reach a decision.